Difference in reduction of endogenous prostaglandin E2 and prostacyclin levels in rat gastric mucosa between pranoprofen and indomethacin.
スポンサーリンク
概要
- 論文の詳細を見る
Non-steroidal antiinflammatory drugs (NSAID) produce the acute gastric mucosal lesions in relation to the inhibition of prostaglandin (PG) biosynthesis in animals and humans. We tested the effect of pranoprofen and indomethacin on gastric mucosal damage and mucosal PGE<SUB>2</SUB> and prostacyclin (PGI<SUB>2</SUB>) levels in a same antiinflammatory dose (ED<SUB>50</SUB> on the carrageenin-induced foot edema) in rats. The animals were intragastrically given pranoprofen three times before sacrifice in a dose of 0.58 mg/kg or indomethacin in a dose of 3.8 mg/kg. Endogenous PGE<SUB>2</SUB> and PGI<SUB>2</SUB> in fundic mucosa were determined by radioimmunoassay. Pranoprofen is less potent than indomethacin to produce the gastric mucosal lesions. The PG levels were not reduced in rats given pranoprofen but were markedly reduced in rats given indomethacin. These results suggest that the ulcerogenicity of pranoprofen is less potent than indomethacin, and this difference may be related to the PG levels in rat gastric mucosa.
- 日本炎症・再生医学会の論文
日本炎症・再生医学会 | 論文
- 新規キノリノン誘導体TA-270の炎症性気道疾患に対する効果
- Salazosulphapyridine, Predonizolone の好中球機能に及ぼす影響と Sodium ferrous citrate との併用効果についての検討
- Sodium ferrous citrate の好中球機能に及ぼす影響
- Mesalazine(Pentasa) の好中球機能に及ぼす影響と Sodium ferrous citrate(SFC) との併用効果についての検討
- 非ウイルスベクターによる細胞標的法の開発